PPARG and myxoma: The clinical results of the experiment confirmed that miR-122-dependent downregulation of MEF2D by PPARg suppresses the proliferation of myxoma cells, suggesting that PPARg may exert its antiproliferative effects by negatively regulating the MEF2D.